Altace Patent Trial Set To Begin Feb. 13
This article was originally published in The Pink Sheet Daily
King Therapeutics' defense against generic competition of ACE inhibitor Altace (ramipril) is scheduled to go to trial in Boston federal court Feb. 13, CEO Brian Markison said Feb. 7 during the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
You may also be interested in...
King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.